Artimplant and Tiller signs an agreement

Artimplant AB (publ) and Tiller International Capital have today entered into an agreement regarding a Sales, Marketing and Distribution Agreement which will gives Tiller the exclusive right to sell, market and distribute all Artimplant´s products outside Europe and non exclusively within Europe.

The detailed operational procedures are expected to be completed within the next four weeks.

The current sales efforts of Artimplant in the USA will be coordinated with Tiller to support both new and existing customers in the best way.

Tiller works extensively with Healthcare groups such as Catholic Healthcare on a Global basis to provide the best possible facilities and treatment for patients. Catholic Healthcare treats 30,000,000 patients a year in its more than 600 hospitals.

“I am very happy and satisfied to enter into this Agreement with Tiller. The Agreement gives Artimplant a good platform to expand the business and also a partner who has a lot of experience from both the US and Global markets”, says Kjell Thörnbring, CEO Artimplant.

Anthony N. Georgiou, Chairman of Tiller says, “With our network in the Healthcare systems and the partners we are cooperating with, we see a huge potential in Artimplant´s products and are looking forward to a very fruitful future together”.

Västra Frölunda, May 30, 2013
Kjell Thörnbring
CEO

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedics. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet as well as shoulder and other soft tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting on the Company's business, including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information that Artimplant will make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 30, 2013 at 11 am (Swedish time).

About Us

Artimplant is a research- and development company, active within bio-materials.